T he use of corticosteroids for the treatment of a variety of musculoskeletal conditions is common practice. [1] [2] [3] [4] [5] [6] Local administration of the drug by injection into the relevant subcutaneous compartment usually results in improved clinical outcome, at least temporarily. [2] [3] [4] [5] [6] Furthermore, when depot formulations are injected intramuscularly, the systemic effects associated with oral delivery are reduced. 2 However, although injections are generally safe, they present some disadvantages and risks (eg, postinjection pain and flare, infection, difficulty in accurately placing the needle, need for an experienced health care professional to perform the injection). 2, 3 Alternatively, iontophoresis also is used in clinical practice to deliver corticosteroids locally. [7] [8] [9] Iontophoresis is a minimally invasive technique that enhances the transport of charged and highly polar molecules across the skin by the application of a small electrical current (with a current density Ͻ0.5 mA/cm 2 ). The 2 main mechanisms of transport of this electrically enhanced method are electromigration and electroosmosis. 8, 10, 11 Electromigration originates from the direct interaction of the electrical field and the ions present in the formulation and the skin and, therefore, will enhance the transport of cationic drugs from the anode and, inversely, negatively charged drugs from the cathode. Conservation of charge requires that the sum of the electrical current carried by each ion equal the total electrical current supplied by the power source. Practically, as far as drug delivery is concerned, this means that the drug competes with all the other ions present in the system. 10, 11 The efficiency of transport, that is, the fraction of the total charge transported by a given drug (its transport number, t d ), can be determined experimentally by measuring its flux (J d ) and applying the relation:
where I is the total current passed, F is the Faraday's constant, and z d is the valence of the drug. 12 Electroosmosis has its origin in the fact that the skin is a negatively charged membrane at physiological pH. When an electrical potential is applied across a membrane containing a fixed charge, a bulk volume flow of solution occurs in the direction of the counterion movement. 13 This means that for the negatively charged skin, the electroosmotic flow is in the anode-to-cathode direction. This assists the transport of cations and retards that of anions. This flow of solvent carries through the skin any dissolved solute and, therefore, is the mechanism enhancing transdermal delivery of neutral, polar molecules. Electroosmotic flow is the dominant mechanism of transport for the delivery of larger molecules. 11 The drug flux due to the electroosmotic mechanism (J d
EO
) is proportional to the concentration (C d ) of the solute:
where v is the solvent volume flow. 14 The formulation's pH and ionic strength are the main parameters that can be used to modulate electroosmosis by, respectively, modifying and screening the skin's charge. 11, 15, 16 Dexamethasone phosphate (Dex-Phos, MW: 472.4), a phosphorylated prodrug of dexamethasone (Dex), undoubtedly has been the most studied corticosteroid for iontophoretic delivery. 8 The disodium salt, dexamethasone sodium phosphate (Dex-Na 2 -Phos, MW: 516.4), is water soluble and at physiological pH is present mainly in its dianionic form (pK a s: 1.9 and 6.4). Iontophoretic treatment of various musculoskeletal problems with Dex-Phos has been the subject of clinical studies, 17-29 many of which have reported beneficial effects. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] However, improvement in the patient's condition is not always seen, 28, 29 perhaps due to the variety of iontophoretic conditions used 8 and to the fact that the optimal conditions for Dex-Phos delivery have not been identified.
The delivery electrode and the formulation of the drug solution are controllable parameters that are expected to greatly influence the efficiency of the delivery. Earlier studies have used the anode to deliver DexPhos, 17, 22, 30 but, given that Dex-Phos is negatively charged at physiological pH (zϳϪ2 at pH 7.4), delivery from the cathode (with electromigration as the main driving force) is more appropriate than that from the anode (electroosmosis being the only available driving force). 9, 11 Furthermore, many clinical studies evaluating the iontophoretic delivery of Dex-Phos have combined the drug with lidocaine hydrochloride. [17] [18] [19] [20] [21] [22] 28 Again, this practice may have a detrimental effect on Dex-Phos delivery due to the introduction of exogenous ions that are competing with the drug for the transport of current through the skin. 9, 11 Thus, there is a need to optimize the conditions for Dex-Phos iontophoresis.
The primary objective of this research, therefore, was to identify the optimal iontophoretic conditions to deliver Dex-Phos. A further goal was to better understand the effects of:
(1) the ions present in the formulation or in the subdermal compartment that are competing with DexPhos to transport the current and (2) the electroosmotic flow, which normally occurs in the anode-tocathode direction, that is, against the electromigration of Dex-Phos delivered from the cathode. † † Silver wire (Ͼ99.99% purity) and silver chloride (99.999%) were purchased from Sigma-Aldrich. All reagents were at least analytical grade, and all aqueous solutions were prepared using high-purity deionized water (18.2 M⍀⅐cm, Barnstead Nanopure Diamond ‡ ‡ ). The concentrations of Dex-Na 2 -Phos solutions are expressed in terms of the Dex-Phos concentration. For example, a 0.4% Dex-Phos solution contains 4.4 mg/mL of Dex-Na 2 -Phos.
Skin Preparation
Porcine ears were obtained from a local abattoir. Ears were cleaned under running cold water, and the skin was dermatomed to a nominal thickness of 750 m (Zimmer Electric Dermatome § § ). The pieces of tissue obtained (ϳ9 cm 2 ) were wrapped individually in Parafilm and stored for no more than 3 months at Ϫ20°C until use. The required pieces of skin then were thawed at room temperature for approximately 30 minutes before each iontophoresis experiment.
Preparation of Dex-Phos Solution at pH 4
In one experiment, a solution of Dex-Phos prepared in deionized water at pH 4 was used. To avoid the inclusion of extraneous anions inevitable when a strong acid is used to lower the pH of a Dex-Na 2 -Phos solution prepared in water (typical pHϭ7.5), an equimolar mixture of the diacid (dexamethasone-dihydrogenphosphate [Dex-H 2 -Phos]) and its conjugate base (Dex-Na 2 -Phos) was dissolved in water to obtain a final concentration of 0.4% of Dex-Phos. Dex-H 2 -Phos was prepared from the disodium salt by adding one part of 37% weight-to-weight ratio HCl to 3 parts of a solution of 25 mM of DexNa 2 -Phos in water. The insoluble dihydrogen acid precipitated and was recovered by liquid extraction using ethyl acetate. The ethyl acetate was evaporated, leaving a powder of Dex-H 2 -Phos, which contained only trace amounts of extraneous ions when assayed by ion chromatography.
Iontophoresis
In vitro iontophoresis experiments were performed in side-by-side diffusion cells, as illustrated in Figure 1 (transport areaϭ0.78 cm 2 ). The skin was clamped between the 2 half cells, with the stratum corneum side facing the donor (drug-containing solution) chamber. In all experiments, the subdermal compartment was filled with phosphate-buffered saline (PBS; 170 mM sodium, 1.4 mM potassium, 137 mM chloride, and 18 mM phosphate) at pH 7.4. Both chambers held 3.5 mL of solution and were magnetically stirred. Thirty minutes prior to iontophoresis, the cathodal chamber was filled with 3.5 mL of deionized water and the anodal chamber was filled with 3.5 mL Schematic diagram of the experimental setup.
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of PBS to check for leaks. Both chambers then were emptied and refilled with the appropriate donor and receptor solutions before the experiment was started. In all experiments, a 0.3-mA constant current intensity (current densityϭ0.38 mA/cm 2 ) was applied for 6 hours via Ag-AgCl electrodes connected to a power source (Yokogawa 7651 Programmable DC source ). All experiments were performed at room temperature with a minimum of 4 replicates using the skin from at least 2 different pigs. To measure the delivery of DexPhos, 1 mL of the subdermal compartment was collected and replaced by the same volume of PBS every hour for the first 2 hours and every half hour thereafter. A 24-hour control experiment, with no electrical current applied, also was performed using Dex-Phos 0.4% in water as the donor solution.
Effect of delivery electrode polarity. First, the effect of the polarity of the delivery electrode was verified for 2 formulations containing sufficient Cl Ϫ to satisfy the electrochemistry at the anode: (1) Dex-Phos 0.4% in 0.9% NaCl and (2) a mixture containing one part of injectable DexPhos (Faulding) for 2 parts of lidocaine hydrochloride.
Effect of donor composition.
Dex-Phos delivery from the cathode was measured for a variety of donor solutions (Tab. 1). The effect of the concentration of the drug in the absence of a background electrolyte was verified for concentrations ranging from 0.2% to 0.8%. In one experiment, to ensure that the concentration of the Cl Ϫ released by the AgAgCl electrode remained an order of magnitude lower than that of the drug in the donor solution (Dex-Phos 0.4% in H 2 O), the latter was continuously perfused (15 mL/h), using a peristaltic pump, during the iontophoretic delivery.
Effect of electroosmosis.
A strategy to reduce electroosmosis against the delivery of Dex-Phos was explored. The approach involved delivery of 0.4% Dex-Phos from a donor solution at pH 4. In the latter iontophoretic conditions and those described in Table 2 , electroosmotic flow was assessed using mannitol (at 10 mM) as a marker. The flux of mannitol was evaluated in both anode-to-cathode and cathode-to-anode directions. In addition to sampling of the receptor chamber, 0. In Vitro Optimization of Dexamethasone Phosphate Delivery by Iontophoresis donor solution was collected hourly. The passive diffusion of mannitol across the skin also was measured as a control.
Contribution of competing ions.
Finally, the donor solution samples obtained in the experiment with mannitol, in the 3 cases described in Table 4 , were assayed for the major competing counterions sodium and potassium. The concentration of the co-ion citrate in the receptor also was measured when Dex-Phos was formulated with this anion. From these values, the contributions of the main competing ions to the total current were determined.
Sample Analysis
The concentrations of Dex-Phos and Dex in the receptor chamber were assayed by high-performance liquid chromatography (ASI-100 automated sample injector, P680 pump, TCC-100 thermostated column compartment, PDA-100 diode array detector, Chromeleon software) ## under isocratic conditions. A mobile phase consisting of 30:70 (volume-to-volume ratio) acetonitrile:phosphate buffer (0.15 M, pH 2) was pumped (0.75 mL/min) through a Lichrosphee 100 RP-18 (4 ϫ 125 mm) reverse-phase column*** fitted with its guard column and thermostated at 25°C. Dex and Dex-Phos concentrations were quantified via their UV absorbance at 240 nm using their respective calibration curves obtained from a minimum of 5 standard solutions (made from 500-ppm stock solutions in methanol appropriately diluted in PBS at pH 7.4) covering the entire range of experimental concentrations. The retention times for DexPhos and Dex were ϳ3.5 and ϳ10.5 minutes, respectively; the detection limit for both was 0.02 g/mL for a 25-L injection, and detection was linear up to 150 g/mL (correlation coefficient Ͼ.999, relative standard deviation Ͻ5%).
Ion chromatography with suppressed conductivity detection (AS50 autosampler and thermal compartment, GP50 gradient pump, ED50 electrochemical detector)
## was used to measure the concentrations of sodium, potassium, and citrate. For the quantification of cations, the 20 mM of methanesulfonic acid eluent was pumped under isocratic conditions (1 mL/min) through an IonPac CS12A column ## (250 ϫ 4 mm) thermostated at 30°C and a CSRS ULTRA II suppressor ## (4 mm) set at a current of 62 mA. Concentrations of Na ϩ and K ϩ were measured against linear calibration curves obtained from standard solutions (at least 5 different concentrations, correlation coefficient Ͼ.998, relative standard deviation Ͻ6%) of their respective chloride salt. For the quantification of citrate anions in the receptor compartment, the 35 mM of NaOH mobile phase was pumped under isocratic conditions (1 mL/min) through an IonPac AS16 column ## (250 ϫ 4 mm) thermostated at 30°C and an ASRS ULTRA II suppressor ## (4 mm) set at a current of 90 mA. At least 5 potassium citrate solutions were used as standards to generate the linear calibration curve (correlation coefficient Ͼ.999, relative standard deviation Ͻ4%).
Analysis of mannitol was performed using ion chromatography coupled with pulsed amperometric detection. ## The mobile phase (380 mM of NaOH) was pumped (0.4 mL/min) through a CarboPac MA1 column ## (250 ϫ 4 mm) maintained at a temperature of 20°C. Again, the linear calibration curve was obtained from at least 5 standards of mannitol in PBS (correlation coefficient Ͼ.999, relative standard deviation Ͻ7%.)
Data Analysis
Linear regressions and statistical analyses were performed using GraphPad Prism V.4.00.
† † † Statistical differences within multiple data sets were assessed by one-way analysis of variance, followed by a Tukey multiple comparison test. The level of statistical significance was fixed at PϽ.05. The fluxes were obtained from the slope of the cumulative amount delivered as a function of time for each replicate and are expressed as mean (SD). The reported Dex-Phos flux is the sum of the Dex-Phos and Dex fluxes into the receptor phase to account for the partial dephosphorylation of the prodrug that occurred during transdermal passage or in the receptor compartment. Transport numbers were calculated using these fluxes and equation 1. The valence used for Dex-Phos in the calculations was 2, unless otherwise stated.
Results

Passive Diffusion Control
The passive diffusion flux of DexPhos from a 0.4% solution in pure water after 6 hours was below the detection limit and reached only 0.13 (0.11) nmol/h at 24 hours. Considering that all iontophoresis experiments lasted 6 hours, the contribution of passive diffusion could be assumed to be negligible compared with electrotransport.
Anodic Versus Cathodic Delivery
Dex-Phos delivery from the anode was compared directly with that from the cathode. Two donor solutions, which contained sufficient Cl Ϫ to ensure good functioning of the Ag-AgCl electrode during anodic delivery, were tested: (1) 0.4% drug in normal saline and (2) a mixture of commercially available citratebuffered injectable Dex-Phos (Faulding, 0.4% weight-to-volume ratio) and lidocaine hydrochloride (4% weight-to-volume ratio). In the former case, cathodal and anodal fluxes were 14 (4) and 0.3 (0.2) nmol/h, respectively; for the latter, the corresponding transport rates were 2.1 (0.6) nmol/h from the cathode and below the level of detection from the anode.
Effect of Donor Composition on Cathodic Delivery
The next logical step was to optimize delivery from the cathode. In the case of the negatively charged Dex-Phos, the efficiency of iontophoretic delivery will be reduced by the presence of competing anions in the donor solution. 11 Dex-Phos flux, therefore, was measured from different formulations, many of which had been used in clinical studies, containing a more or less constant concentration of the drug together with a range of background electrolytes.
The Dex-Phos solutions tested, the drug's flux, and the corresponding transport numbers are reported in Table 1 . The pH of all solutions tested, except the mixture of DexPhos and lidocaine, was between 7.2 and 7.9, meaning that Ͼ85% of the drug carried a charge of Ϫ2. For the Dex-Phos/lidocaine formulation, the pH was 6.8, and only ϳ70% of the drug had a charge of Ϫ2. However, because in all cases the majority of the drug was doubly charged, the value for z in equation 1, which was used to determine the transport number from the flux, was assumed equal to 2.
Clearly, the absence of background electrolyte (Dex-Phos in pure water and the injectable Dex-Phos formulation from Organon Laboratories containing a neutral molecule, glycerol, for isotonicity) greatly improved drug delivery. These 2 solutions resulted in fluxes that were not significantly different.
The donor solution in 40 mM of potassium citrate resulted in a Dex-Phos flux not significantly different from those from the commercially available Faulding and American Regent injectable solutions, which contain sodium citrate for isotonicity. When Dex-Phos was formulated with 0.9% (154 mM) NaCl rather than 40 mM of sodium citrate, the drug flux was slightly increased (PϽ.05), but remained much smaller than that in the absence of background electrolyte.
Next, improving Dex-Phos delivery by varying the drug concentration in the donor solution in the absence of background electrolyte was explored. In the case of cations, when no background electrolyte is present, the electromigration flux is rather independent of the drug concentration in the donor, 10, 11, 31 For anions, however, when Ag-AgCl electrodes are used, there is Cl Ϫ release from the electrode and the potential for competition to evolve over time. 32 Nevertheless, as shown in Figure 2 , when the Dex-Phos concentration was varied by 4-fold (0.2% to 0.8% weight-to-volume ratio), there was no significant difference in the drug flux measured after 6 hours of iontophoresis, and these values did not differ from that obtained when the donor solution was continuously perfused at the high rate of 15 mL/h to ensure that the Cl Ϫ concentration never attained one tenth that of Dex-Phos.
Effect of Electroosmosis
To evaluate the effect of electroosmosis on the delivery of Dex-Phos, the flux of mannitol in the anode-tocathode direction and its equivalent solvent flow were measured for the 4 delivery conditions summarized in Table 2 . The mannitol fluxes also were measured in the cathode-toanode direction and were not significantly different from the negligible passive diffusion of the neutral marker (1.0 [0.6] nmol/h). Electroosmosis occurred against Dex-Phos delivery from the cathode. Solvent flow was maximal when no background electrolyte was present in the donor (Dex-Phos 0.4% in H 2 O), the condition so far identified as "optimal" for Dex-Phos delivery. Electroosmotic flow was significantly higher when the background electrolyte was potassium citrate compared with sodium chloride (PϽ.05). The presence of Dex-Phos in the anode, as opposed to the cathode, when normal saline acted as background electrolyte, did not signifi-
Figure 2.
Dexamethasone phosphate (Dex-Phos) iontophoretic flux as a function of concentration in deionized water. In the 0.4% perfused Dex-Phos (PD) experiment, the donor solution was continuously perfused with 0.4% weight-to-volume ratio Dex-Phos.
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cantly affect the level of electroosmotic flow.
A strategy then was explored to reduce (or reverse) the skin's negative charge in order to decrease the electroosmotic flow and thereby enhance the delivery of the drug. The Dex-Phos 0.4% in H 2 O solution was prepared at pH 4 using a mixture of the diacid (Dex-H 2 -Phos) and the disodium salt (Dex-Na 2 -Phos). The idea was to reduce the negative charge on the skin, the isoelectric point of which has been shown to be between 4 and 5. 33 As shown in Table  3 , mannitol delivery was clearly reduced at pH 4, and convective solvent flow decreased, but this had no impact on the electrotransport of Dex-Phos.
Transport Numbers of Main Ionic Species
Finally, the transport numbers of the main ionic species present in the different experimental conditions studied were measured (Tab. 4). It was clear that sodium was the major charge carrier across the skin, contributing more than 70% in all cases. Only when the pH was reduced to 4 was the Na ϩ transport lowered (PϽ.05). In addition, although all donor solutions eliminated Cl Ϫ , the AgAgCl electrochemistry resulted in the progressive release of this anion into the donor solution such that a significant contribution to the movement of charge could be deduced for this anion.
Discussion and Conclusions Electroosmosis
Dex-Phos delivery from the cathode proceeded against electroosmotic flow. The latter increased when the background electrolyte was removed from the drug solution in good agreement with previous reports. 13, 15 Lowering the pH of the Dex-Phos donor solution to 4 reduced the electroosmotic flow in the anode-tocathode direction as previously observed. 15, 33 Consistent with the reduction of electroosmotic flow, the transport number of Na ϩ was significantly smaller as well, reflecting a change in the skin's permselectivity. However, the lower pH in the donor solution failed to improve drug delivery, suggesting that the altered electroosmotic flow has a negligible effect on the electrotransport of the drug.
Dex-Phos delivery from the anode was really inefficient and, therefore, should be avoided in the clinic. This conclusion contradicts an early study in which the drug was iontophoresed in vivo, in a monkey, from the anode and resulted in measurable levels in deep underlying structures. 30 Although the exact reasons for this discrepancy are still unclear, 2 comments on the latter study can be made in that respect: (1) a relatively important drug concentration (Ͼ2 g/g) in subdermal structures (depth Ͼ3 mm) was observed after a short application of the drug (20 minutes) in absence of current, which raises the question whether the skin barrier in this animal model was compromised; and (2) the current density used (0.94 mA/cm 2 ) is nearly twice the maximum tolerable level in humans (0.5 mA/cm 2 ) 34 and could have altered the skin barrier.
Ionic Competition
Not all commercially available DexPhos solutions are equivalent for iontophoresis. The ideal donor solution contains no background electrolyte to compete with the drug to carry a charge across the skin. Trends similar to those observed in this study had been observed, but to a lesser extent due to a much higher passive diffusion contribution, when Dex-Phos was iontophoresed across an artificial membrane. 35 The DexPhos/lidocaine formulation resulted in a Dex-Phos flux much less than those from all other formulations due to the high levels of chloride and citrate present. Although lidocaine hydrochloride increases the buffer capacity of the donor solution, 9 this is not necessary when Ag-AgCl electrodes are used because problems associated with pH changes are avoided. 32 In fact, in the experiments reported here, the pH of the donor solution never varied by more than 0.2 pH unit over the 6 hours of iontophoresis.
Even in optimal delivery conditions, the transport number of Dex-Phos was relatively small, with values just over 0.01. This was most likely due to the rather poor mobility of the drug inside the membrane resulting from its relatively large molecular weight. Similarly, the transport numbers of cations were found to fall off rapidly with molecular weight, with values approaching zero at 400 to 500 Da. 36 The principal ionic species carrying electrical current during delivery of Dex-Phos from water was the subdermal counterion Na ϩ . Even when citrate was present, the transport number of sodium was Ͼ80%. This value is in good agreement with the transport number of sodium previously observed when the competing counterion was gluconate, an anion with a molecular weight very similar to that of citrate. 37 Interestingly, the release of Cl Ϫ from the Ag-AgCl cathode during iontophoresis of Dex-Phos from water did not significantly affect drug transport over the course of the experiment. Given the amount of Cl Ϫ produced (ϳ67 mol, corresponding to a concentration of ϳ19 mM), it is surprising (and, for the moment, not fully understood) that the Dex-Phos flux did not decrease somewhat after 6 hours of current passage. From a practical standpoint, however, this is a positive result, as an iontophoretic delivery device for Dex-Phos would not require complex characteristics, such as an ion-exchange membrane to sequester Cl Ϫ . 32 
Other Practical Issues
The steady-state flux of Dex-Phos from water (ϳ70 nmol/h at a current of 0.3 mA, or ϳ2 g/mA⅐min) translates to the delivery of about 0.16 mg from a typical current "dose" of 80 mA⅐min. Although this is rather less than that administered via injection (1 mL of a 0.4% weight-to-volume ratio solution contains 4 mg), it is significantly greater than that resulting from iontophoresis of the DexPhos formulations containing citrate (ϳ0.02 mg) and lidocaine (again, ϳ0.02 mg), as reported previously. 9 In vivo, the current "dose" typically is delivered over 20 minutes, and a steady-state flux is unlikely to be achieved in this time span (in the experiments reported here [data not shown], a lag time of about 30 -60 minutes was observed). The kinetics of transport and uptake in vivo are typically more rapid than those seen in vitro due to the presence of a fully functional microcirculation, which can "clear" the drug to the underlying tissue and, ultimately, the systemic circulation. Furthermore, it is known that in vivo uptake and absorption can be influenced significantly by, for example, local vasoconstriction. 38 
Clinical Implications
The simple in vitro model used in this study cannot perfectly replicate the much more complex in vivo situation in humans. However, porcine skin, even when stored frozen before use, is a good model for human skin, 33, 39 and the trends observed here also may be expected in vivo. To optimize Dex-Phos delivery, the drug must be delivered from the cathode, and the formulation should exclude, as far as possible, the presence of competing co-ions. If commercially available Dex-Phos solutions are used, preference should be given to those that contain the least amounts of anions such as chloride and citrate. Ultimately, well-designed in vivo studies will be necessary to demonstrate the efficiency of iontophoresis to deliver clinically relevant corticosteroid doses in soft tissues, and the results presented here should be of particular importance for their design. 
